RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemia: drug combo targets hidden cancer cells
Disease control OngoingThis early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail of cancer drugs shows promise in early leukemia trial
Disease control OngoingThis early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Promising new combo targets Hard-to-Treat infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…
Matched conditions: RECURRENT MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC